Clinical trials: Polymyalgia Rheumatica (PMR)
Polymyalgia Rheumatica
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154
Polymyalgia rheumatica (PMR) is an inflammatory disease causing shoulder, hip, and neck pain and stiffness, in adults aged 50 years or older.
- Trial name
- AIM-PMR (NCT04972968)
- Testing
- ABBV-154, Glucocorticoid
- Where
- 117 sites in United States, Australia and 13 more
- Volunteers
- 181 people
- Sponsor
- AbbVie
Polymyalgia Rheumatica (PMR)
Study of Tocilizumab to Treat Polymyalgia Rheumatica
This is a fifteen-month open label, Phase IIa clinical trial is being conducted to assess the tolerability, safety and efficacy of a medication called Tocilizumab (Actemra®) in patients with polymyalgia rheumatica (PMR).
- Trial name
- NCT01396317
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hospital for Special Surgery, New York
Polymyalgia Rheumatica
Timed Release Tablet Prednisone in Polymyalgia Rheumatica
Polymyalgia Rheumatica (PMR) is a disease that usually affects older people. Patients complain of stiffness and pain around the shoulders and hips. The stiffness is more severe in the morning.
- Trial name
- NCT00836810
- Testing
- Timed Release Tablet Prednisone, Prednisolone
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust